Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2022, Review
2022

Inactivation of pathogens in pediatric transfusiology

Review
Published 2022-09-20
Eugene B. Zhiburt
Pirogov National Medical and Surgical Center, Health Ministry of Russian Federation; 70 Nizhnyaya Pervomayskaya Str., Moscow 105203, Russia;
ФГБУ «Национальный медико-хирургический центр имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации; Россия, 105203 Москва, ул. Нижняя Первомайская, 70;
https://orcid.org/0000-0002-7943-6266 (unauthenticated)
Ramil G. Khamitov
Republican Blood Transfusion Station; 41/1, Batyrskaya Str., Ufa 450106, Russia
ГБУЗ «Республиканская станция переливания крови»; Россия, 450106 Уфа, ул. Батырская, 41/1
https://orcid.org/0000-0002-1068-3816 (unauthenticated)
Leonid D. Shalygin
Pirogov National Medical and Surgical Center, Health Ministry of Russian Federation; 70 Nizhnyaya Pervomayskaya Str., Moscow 105203, Russia;
ФГБУ «Национальный медико-хирургический центр имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации; Россия, 105203 Москва, ул. Нижняя Первомайская, 70;

Keywords

blood
donor
platelets
plasma
transfusion
inactivation of pathogens
safety
children
  Full Text

Abstract

Summary. Introduction. To increase the infectious safety of blood products, methods of pathogen inactivation in a donor container are used. In Russia, 3 technologies for pathogen inactivation in fresh frozen plasma have been approved — Theraflex (methylene blue and light), Intercept (amotosalen and ultraviolet (UV) A), Mirasol (riboflavin and UV) as well as 2 technologies for pathogens inactivation in platelet concentrates — Intercept and Mirasol. Objective: to study the results of transfusion of pathogen-reduced blood components in pediatric practice. Materials/Methods. A search was carried out in Russian electronic libraries (eLibrary.ru) and USA (pubmed.ncbi.nlm.nih.gov) by words in Russian and English: «children», «pediatric», «pathogen inactivation», «blood transfusion», «methylene», «amotosalen», «riboflavin». Results. Eight studies of transfusion of pathogen-reduced blood components to children were found. Platelet transfusions were the subject of 6 studies (4 — Intersept and 2 — Mirasol) and plasma transfusions — subject of 2 studies (Theraflex), 2 studies were carried out in Russia. General patterns can be identified: a) there is no decrease in the effectiveness of pathogen-reduced components in comparison with standard ones; b) frequency use of pathogen-reduced products and their consumption per recipient in comparison with standard products may be slightly increased; c) the frequency of transfusion reactions during transfusion of pathogen-reduced platelets and plasma does not increase. Conclusions. The studies collected in this review provide evidence of the safety and efficacy of transfusion of pathogen-reduced blood components to children. This is also evidenced by the data of Russian hemovigilance. However, studies are sparse and hemovigilance data are passive and may overlook minor or unrecognized reactions. The efficacy of pathogen-reduced platelets in the treatment of pediatric patients with trauma and massive bleeding remains to be studied. The reliable results of numerous long-term studies will make the daily work of the blood service more confident.

References

  1. Shevchenko Yu.L., Karpov O.E., Zhiburt E.B. Blood transfusion: history and modernity (to the 100th anniversary of blood transfusion in Russia). Vestnik Nacional’nogo mediko-hirurgicheskogo centra imeni N.I. Pirogova. 2019;14(4):4–11. (In Russ.). DOI: 10.25881/ BPNMSC. 2020.29.78.001.

  2. Жибурт Е.Б. Переливание крови детям. М.: Национальный медико-хирургический центр имени Н.И. Пирогова, 2018. 58 с. Zhiburt E.B. Blood transfusion for children. Moscow: Pirogov National Medical and Surgical Center, 2018. 58 рp. (In Russ.).

  3. Goel R., Josephson C.D., Patel E.U. et al. Individual- and hospital-level correlates of red blood cell, platelet, and plasma transfusions among hospitalized children and neonates: a nationally representative study in the United States. Transfusion. 2020;60(8):1700– 12. DOI: 10.1111/trf.15855.

  4. Жибурт Е.Б. Вопросы гемостаза в правилах заготовки, хранения, транспортировки и клинического использования донорской крови и ее компонентов. Тромбоз, гемостаз и реология. 2019;(4):9–12. DOI: 10.25555/THR.2019.4.0894.

    Zhiburt E.B. Issues of hemostasis in the rules of procurement, storage, transportation and clinical use of donated blood and its components. Tromboz, gemostaz i reologiya. 2019;(4):9–12. (In Russ.). DOI: 10.25555/THR.2019.4.0894.

  5. Donato H. Neonatal thrombocytopenia: A review. II. Non‐immune thrombocytopenia; platelet transfusion. Arch Argent Pediatr. 2021;119(4):e303‐e314. DOI: 10.5546/aap. 2021.eng.e303.

  6. Bruun M.T., Yazer M.H., Spinella P.C. et al. Vox Sanguinis International Forum on pediatric indications for blood component transfusion: Summary. Vox Sang. 2019;114(5):523–30. DOI: 10.1111/ vox.12763.

  7. Roth W.K., Busch M.P., Schuller A. et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang. 2012;102(1):82–90. DOI: 10.1111/j.1423–0410.2011.01506.x.

  8. Жибурт Е.Б., Мадзаев С.Р. Заготовка и переливание тромбоцитов. М.: РАЕН, 2013. 376 с.
    Zhiburt E.B., Madzaev S.R. Platelets collection and transfusion. Moscow: RAEN, 2013. 376 pр. (In Russ.).

  9. Кузнецов С. И., Аверьянов Е. Г., Шестаков Е. А., Жибурт Е. Б. Ошибка регламента скрининга бактерий в компонентах донорской крови. Менеджер здравоохранения. 2021;(5):51–6.

    Kuznetsov S.I., Averyanov E.G., Shestakov E.A., Zhiburt E.B. Error in the procedure for screening bacteria in donor blood components. Menedzher zdravoohraneniya. 2021;(5):51–6. (In Russ.).

  10. Zeller M.P., Ellingham D., Devine D. et al. Vox Sanguinis International Forum on Donor Incentives: Summary. Vox Sang. 2020;115(4):339–44. DOI: 10.1111/vox.12868.

  11. Krishnaswamy S., Ageno W., Arabi Y. et al. Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Res Pract Thromb Haemost. 2021;5(5): e12532. DOI: 10.1002/rth2.12532.

  12. Жибурт Е.Б., Губанова М.Н., Прокофьева И.В. Вопросы гемостаза в проекте правил заготовки, хранения, транспортировки и клинического использования донорской крови и ее компонентов. Тромбоз, гемостаз и реология. 2016;(4):13–8.

    Zhiburt E.B., Gubanova M.N., Prokofieva I.V. Issues of hemostasis in the draft rules for the procurement, storage, transportation and clinical use of donated blood and its components. Tromboz, gemostaz i reologiya. 2016;(4):13–8. (In Russ.).

  13. Lozano M., Cid J., Prowse C. et al. Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature. Transfusion. 2015;55(3):690. DOI: 10.1111/trf.12996.

  14. Жибурт Е.Б., Кузнецов С.И., Чемоданов И.Г. и др. Новое в трансфузиологии (на виртуальном конгрессе Международного общества переливания крови). Трансфузиология. 2021;22(1):47–64.

    Zhiburt E.B., Kuznetsov S.I., Chemodanov I.G. et al. New in transfusiology (at the virtual congress of the International Society of Blood Transfusion). Transfuziologiya. 2021;22(1):47–64. (In Russ.).

  15. Губанова М. Н., Чемоданов И. Г., Гайворонская В. В. и др. Инактивация патогенов в клеточных компонентах крови. Трансфузиология. 2017;18(3):15–36.
    Gubanova M.N., Chemodanov I.G., Gaivoronskaya V.V. et al. Inactivation of pathogens in the cellular components of the blood. Transfuziologiya. 2017;18(3):15–36. (In Russ.).

16. McDonald C.P., Bearne J., Aplin K., Sawicka D. Assessing the inactivation capabilities of two commercially available platelet component pathogen inactivation systems: effectiveness at end of shelf life. Vox Sang. 2021;116(4):416–24. DOI: 10.1111/vox.13040.

17. Allen E.S., Cohn C.S., Bakhtary S. et al. Current advances in transfusion medicine 2020: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. Transfusion. 2021;61(9):2756–67. DOI: 10.1111/trf.16625.

18. Snyder E., McCullough J., Slichter S.J. et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion. 2005;45(12):1864–75. DOI: 10.1111/j.1537– 2995.2005.00639.x.

19. Knutson F., Osselaer J., Pierelli L. et al. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen‐UVA photochemical treatment. Vox Sang. 2015;109(4):343–52. DOI: 10.1111/vox.12287.

20. Trakhtman P., Karpova O., Balashov D. et al. Efficacy and safety of pathogen‐reduced platelet concentrates in children with cancer: a retrospective cohort study. Transfusion. 2016;56(Suppl 1):24–8. DOI: 10.1111/trf.13332.

21. Jimenez‐Marco T., Garcia‐Recio M., Girona‐Llobera E. Use and safety of riboflavin and UV light‐treated platelet transfusions in children over a five‐year period: focusing on neonates. Transfusion. 2019;59(12):3580–8. DOI: 10.1111/trf.15538.

22. Schulz W.L., McPadden J., Gehrie E.A. et al. Blood utilization and transfusion reactions in pediatric patients transfused with conventional or pathogen reduced platelets. J Pediatr. 2019;209:220– 5. DOI: 10.1016/j.jpeds.2019.01.046.

23. Григорьянц Р. Г., Самсонова Н. Н., Осилов К. К. и др. Первый опыт применения вирусинактивированной донорской плазмы во время операций на сердце и сосудах у новорожденных и детей первого года жизни. Клиническая физиология кровообращения. 2010;(3):53–65.

Grigoryants R.G., Samsonova N.N., Osilov K.K. et al. The first experience of using virus‐inactivated donor plasma during operations on the heart and blood vessels in newborns and children in the first year of life. Klinicheskaya fiziologiya krovoobrashcheniya. 2010;(3):53–65. (In Russ.).

24. New H., Tinegate H., Hunt L. et al. Methylene blue treated plasma. Joint UK BTS/HPA Professional Advisory Committee/ Serious Hazards of Transfusion (SHOT) Position Statement. 2012. Available at: https://www.transfusionguidelines.org/documentlibrary/position‐statements.

25. Hsien S., Dayton J.D., Chen D. et al. Hemostatic efficacy of pathogen‐reduced platelets in children undergoing cardiopulmonary bypass. Transfusion. 2022;62(2):298–305. DOI: 10.1111/ trf.16768.

26. Филина Н.Г., Мадзаев С.Р., Марьясова Е.В., Жибурт Е.Б. Трансфузионные реакции при переливании плазмы. Трансфузиология. 2014;15(3):38–43.
Filina N.G., Madzaev S.R., Maryasova E.V., Zhiburt E.B. Transfusion reactions during plasma transfusion. Transfuziologiya. 2014;15(3):38–43. (In Russ.).

27. Румянцев А.Г., Мадзаев С.Р., Филина Н.Г. и др. Эффективность переливания тромбоцитов. Гематология. Трансфузиология. Восточная Европа. 2015;(2):16–24.
Rumyantsev A.G., Madzaev S.R., Filina N.G. et al. Efficiency of platelet transfusion. Gematologija. Transfuziologija. Vostochnaja Evropa. 2015;(2):16–24. (In Russ.).

28. Эйхлер О.В., Чечеткин А.В., Аджигитова Е.В. и др. Характеристика осложнений, возникших после переливания донорской кровии ее компонентов, в медицинских организациях Российской Федерации в 2018 году. Трансфузиология. 2019;20(4):301–9.

Eikhler O.V., Chechetkin A.V., Adzhigitova E.V. et al. Characteristics of complications after donor blood transfusion and its components in medical organizations of the Russian Federation in 2018. Transfuziologiya. 2019;20(4):301–9. (In Russ.).

29. Zaffanello M., Piacentini G., Nosetti L., Franchini M. The use of convalescent plasma for pediatric patients with SARS‐CoV‐2: A systematic literature review. Transfus Apher Sci. 2021;60(2):103043. DOI: 10.1016/j.transci.2020.103043.

30. Михайлова Ю.В., Кувшинов М.В., Тюкина Л.Ю. и др. Серопревалентность к SARS‐CoV‐2 у доноров‐реконвалесцентов. Трансфузиология. 2022;21(3):212–7.
Mikhailova Yu.V., Kuvshinov M.V., Tyukina L. Yu. et al. Seroprevalence to SARS‐CoV‐2 in convalescent donors. Transfuziologiya. 2022;21(3):212–7. (In Russ.).

31. Kostin A.I., Lundgren M.N., Bulanov A.Y. et al. Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma. Vox Sang. 2021;116(6):665–72. DOI: 10.1111/vox.13056.

32. Эйхлер О.В., Чечеткин А.В., Аджигитова Е.В. и др. Характеристика реакций и осложнений, возникших в связи с трансфузией донорской крови и ее компонентов, в медицинских организациях Российской Федерации в 2019 году. Трансфузиология. 2020;21(4):304–12.

Eikhler O.V., Chechetkin A.V., Adzhigitova E.V. et al. Characteristics of reactions and complications arising in connection with the transfusion of donated blood and its components in medical organizations of the Russian Federation in 2019. Transfuziologiya. 2020;21(4):304–12. (In Russ.).